Jeff Marrazzo
FounderFounder at Dispatch Biotherapeutics
Philadelphia, Pennsylvania, United States
FoundedDispatch Biotherapeutics
About
Jeff Marrazzo co-founded Spark Therapeutics and served as its CEO from 2013 to 2022, during which the company developed and launched LUXTURNA, the first FDA-approved gene therapy for a genetic disease in the United States, and was sold to Roche in 2019 for $4.8 billion. He is the founding chairman of the board at Dispatch Bio and serves on the boards of Chroma Medicine, Prime Medicine, and nonprofits including The Children's Hospital of Philadelphia, Life Science Cares, and The Rendell Center for Civics and Civic Engagement. Marrazzo holds bachelor's degrees in systems science and engineering and in economics from the University of Pennsylvania and master's degrees in business and public administration from Wharton and Harvard University.
Founder at Dispatch Biotherapeutics
Intro paths
In turn, Jeff can intro founders to Dispatch Biotherapeutics's investors below.
Dispatch Biotherapeutics's investors · 1
Co-founders at Dispatch Biotherapeutics
Experience
- Dispatch BioFounding Chairman of the Boardcurrent2022 — presentPhiladelphia, Pennsylvania, United States
- Nava TherapeuticsBoard Member and Special Advisor to Chief Executive Officercurrent2024 — presentPhiladelphia, PA
- Prime Medicine, Inc.Executive Chairman of the Boardcurrent2023 — present
- nChroma BioChairman of the Boardcurrent2022 — present
- Marrazzo Family FoundationPhilanthropistcurrent2019 — present
- Children's Hospital of PhiladelphiaMember Board of Trusteescurrent2023 — present
- Life Science Cares PhiladelphiaMember, Board of Managers2019 — 2025Greater Philadelphia
- Spark Therapeutics, Inc.Chief Executive Officer and Co-Founder2011 — 2022Greater Philadelphia Area
- Biotechnology Innovation OrganizationBoard Member2017 — 2020
Frequently asked questions
- Who is Jeff Marrazzo?
- Jeff Marrazzo co-founded Spark Therapeutics and served as its CEO from 2013 to 2022, during which the company developed and launched LUXTURNA, the first FDA-approved gene therapy for a genetic disease in the United States, and was sold to Roche in 2019 for $4.8 billion. He is the founding chairman of the board at Dispatch Bio and serves on the boards of Chroma Medicine, Prime Medicine, and nonprofits including The Children's Hospital of Philadelphia, Life Science Cares, and The Rendell Center for Civics and Civic Engagement. Marrazzo holds bachelor's degrees in systems science and engineering and in economics from the University of Pennsylvania and master's degrees in business and public administration from Wharton and Harvard University.
- Where does Jeff Marrazzo work?
- Jeff Marrazzo is Founder of Dispatch Biotherapeutics.
- What companies did Jeff Marrazzo found?
- Jeff Marrazzo founded Dispatch Biotherapeutics.
- Where did Jeff Marrazzo go to school?
- Jeff Marrazzo studied at The Wharton School (Master of Business Administration (MBA), Health Care Management); Harvard University (Master of Public Administration (MPA)); University of Pennsylvania (Bachelor of Science in Engineering, Systems Science and Engineering).
Founder mafias
The Wharton School mafia356
Also came through, then founded or led a company.
+ 349 more
University of Pennsylvania mafia305
Also came through, then founded or led a company.
%20(1).webp)
+ 298 more
Dispatch Biotherapeutics mafia2
Also came through, then founded or led a company.
nChroma Bio mafia2
Also came through, then founded or led a company.
Same school
Also attended The Wharton School2,000
+ 1,994 more
Also attended Harvard University1,961
+ 1,955 more
Also attended University of Pennsylvania1,084
+ 1,078 more
Shared employers
Also worked at Dispatch Bio2
Also worked at nChroma Bio2
Also worked at Children's Hospital of Philadelphia16
+ 10 more
